-
公开(公告)号：EP1337859A1
公开(公告)日：2003-08-27
申请号：EP01972393.1
申请日：2001-10-05
申请人： Mohler, Hanns , Rudolph, Uwe
发明人： Mohler, Hanns , Rudolph, Uwe
CPC分类号： G01N33/94 , A61K31/00 , A61K31/5513
摘要： The present invention relates to selective anxiolytic therapeutic agents which allow for the treatment of anxiety-related disorders with less severe side-effects, such as sedative and amnesic effects, and in particular, dependence liability. These selective agents selectively or preferentially bind the α2-GABAA receptor, as compared to the α1-GABAA receptor. Alternatively, these selective agents selectively or preferentially activate the α2-GABAA receptor, as compared to the α1-GABAA receptor. The present invention also relates to methods for identifying such selective anxiolytic therapeutic agents. The present invention also relates to methods for identifying a molecule that decreases binding of a benzodiazepine to the α1-GABAA receptor, but not substantially to the α2-GABAA receptor.
-
2.发明公开
公开(公告)号：EP0996453A1
公开(公告)日：2000-05-03
申请号：EP98924521.2
申请日：1998-06-23
申请人： Mohler, Hanns , Boison, Detlev
发明人： Mohler, Hanns , Boison, Detlev
CPC分类号： A61K31/7076 , A61K9/0085 , A61K31/704 , A61K38/00 , C12N15/1137 , C12N2310/111
摘要： The present invention relates to the treatment of conditions associated with neuronal activity. Specifically, the invention is drawn to methods and compositions for administering adenosine to inhibit pain syndromes or epilepsy in a patient.
-
3.发明授权
公开(公告)号：EP0996453B1
公开(公告)日：2004-04-28
申请号：EP98924521.2
申请日：1998-06-23
申请人： Mohler, Hanns , Boison, Detlev
发明人： Mohler, Hanns , Boison, Detlev
CPC分类号： A61K31/7076 , A61K9/0085 , A61K31/704 , A61K38/00 , C12N15/1137 , C12N2310/111
-
-
搜索结果
3 条记录 (耗时 0.008 秒)
